KRS Global Biotechnology, Inc. Announces the Compounded Service of Nitroglycerin.

KRS Global Biotechnology, Inc., an FDA registered and inspected 503B Human Outsourcing Facility that specializes in the preparation of drugs no longer commercially available or in short supply, announces today that they are providing the service of compounded nitroglycerin.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

KRS Global Biotechnology

‘There seems to be no resolution to drug shortages soon. Therefore, hospitals should consider planning ahead and using other alternative sources, such as Outsourcing Facilities, for their drug shortages needs.’

Boca Raton, FL (PRWEB) July 20, 2014

KRS Global Biotechnology, Inc. is pleased to announce that it is providing the compounding service of nitroglycerin. Aside from authorized international shipments of the drug into the United States, the company is the only FDA registered and inspected Outsourcing Facility providing the service of compounded nitroglycerin.

As first reported in the New York Times in March 2014, this medication is vital in emergency settings to assist with managing chest pain and severe hypertensive situations. However, supply shortages and recalls from major drug manufactures have caused an alarm from the medical community. The Primary reason for concern is there is no real substitute for the IV form of nitroglycerin.

http://www.nytimes.com/2014/03/26/business/nitroglycerin-a-staple-of-emergency-rooms-is-in-short-supply.html

According to the American Society of Health System Pharmacists, over 300 drugs are in short supply. Thirty percent are due to manufacturing delays. Although the FDA has taken action on this to encourage drug manufacturers to produce more, they cannot force them to increase production on a particular drug.

http://formularyjournal.modernmedicine.com/formulary-journal/news/iv-nitroglycerin-shortage-concerning-manageable?page=full

A representative from the company states that, ‘there seems to be no resolution to drug shortages soon. Therefore, hospitals should consider planning ahead and using other alternative sources, such as Outsourcing Facilities, for their drug shortages needs.’ This echoes the voice of the FDA, which has posted several letters to healthcare professionals with their recommendations that Human Outsourcing Facilities be used for their immediate medication needs.

About KRS Global Biotechnology, Inc.

KRS Global Biotechnology, Inc. has been serving the Healthcare Community since 2001. KRS Global is an FDA registered and inspected Human Outsourcing Facility that specializes in providing medications that are not commercially available or in short supply from distributors & manufacturers.


Contact